The Carlos III Health Institute (ISCIII) is once again collaborating with AstraZeneca in the tenth edition of its awards for young researchers. For another year, the ISCIII will be responsible for analyzing and evaluating the proposals received, ensuring a rigorous process to select the most promising projects in the health field.
How the scientific evaluation process works 🔬
The ISCIII will apply its peer review system to examine each project. Evaluators will analyze the methodology, potential impact, and feasibility of the proposals. This process includes criteria such as the originality of the hypothesis, the experimental design, and the team's ability to carry out the research. The goal is to identify works that bring concrete advances in areas such as oncology, rare diseases, or public health, without losing sight of technical quality.
Young science seeks its dose of recognition 💡
Because, of course, nothing motivates a researcher more than spending months drafting a proposal only to receive validation from a committee. At least the awards come with a check and not just a diploma to hang on the lab wall. And hey, if the ISCIII brings the seriousness, AstraZeneca brings the spotlight. A win-win where everyone gains, except perhaps those who don't make the cut.